港股異動 | 申洲國際(2313.HK)逆勢跌近7% 越南連續五天單日新增病例過萬 防疫措施不斷升級
格隆匯8月24日丨申洲國際(2313.HK)逆勢跌近7%,暫錄三連跌,報170港元,總市值2555億港元。據越南衞生部23日晚發佈的信息,越南當天報吿新增新冠確診病例10280例,連續第五天單日新增確診病例數過萬,累計確診358456例,累計死亡8666例。以越南最大城市胡志明市為主的南部省市疫情形勢嚴峻,迫使政府不斷升級防疫措施。軍隊增援士兵從23日起部署在胡志明市各個區域的街道和檢查站加強巡邏檢查。申洲國際在越南西寧省有布料生產基地,在胡志明市有製衣工廠。2020年,越南和柬埔寨生產基地已為申洲國際貢獻了近四成的成衣產能。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.